Your browser doesn't support javascript.
loading
Atezolizumab-Induced Acrodermatitis and Pustular Psoriasis in a Patient with Non-Small Cell Lung Cancer: A Rare Case Report.
Fattore, Davide; Esposito, Gianluca; Carangelo, Ludovica; Luciano, Maria Antonietta; Megna, Matteo.
Afiliación
  • Fattore D; Department of Clinical Medicine and Surgery, Section of Dermatology, University of Naples "Federico II", Naples, Italy.
  • Esposito G; Department of Clinical Medicine and Surgery, Section of Dermatology, University of Naples "Federico II", Naples, Italy.
  • Carangelo L; Department of Neuroscience, Reproductive Sciences and Dentistry, "Federico II" University, Naples, Italy.
  • Luciano MA; Department of Clinical Medicine and Surgery, Section of Dermatology, University of Naples "Federico II", Naples, Italy.
  • Megna M; Department of Clinical Medicine and Surgery, Section of Dermatology, University of Naples "Federico II", Naples, Italy.
Case Rep Dermatol ; 16(1): 42-46, 2024.
Article en En | MEDLINE | ID: mdl-38384677
ABSTRACT

Introduction:

Immune checkpoint inhibitors are new drugs approved for the treatment of many types of malignancies. Despite their wide use and unquestionable clinical benefits, these agents have also been associated with a unique spectrum of side effects known as immune-related adverse events. In this study, we report the first case of atezolizumab-induced pustular psoriasis and acrodermatitis. Case Presentation A 61-year-old woman presented to our department with erythematous-desquamative and pustular lesions involving all hands and feet fingers, inguinal region, and trunk, associated to severe psoriatic onychodystrophy. She was affected by non-small-cell lung carcinoma from 12 years, and 7 months before admission, she started a treatment with atezolizumab.

Conclusion:

Immune checkpoint inhibitors such as atezolizumab are linked to a plethora of adverse events. Identifying and treating certain adverse skin events, particularly in cancer patients, can be a challenge, leading oncologists to discontinue immunotherapy. Our case shows how it is necessary to have a shared therapeutic algorithm in order to manage serious skin reactions in cancer patients and avoid disruption of the oncotherapy.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Case Rep Dermatol Año: 2024 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Case Rep Dermatol Año: 2024 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Suiza